Novartis

Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Fierce Pharma
congress
drug pricing
Novartis
Amgen
Mallinckrodt
Flag link:
Novartis sells $2.1B in bonds to increase access to its drugs in disadvantaged countries
Novartis sells $2.1B in bonds to increase access to its drugs in disadvantaged countries
Beckers Hospital Review
Novartis
bonds
access
Flag link:
FDA sets back Novartis plans to expand use of SMA gene therapy
FDA sets back Novartis plans to expand use of SMA gene therapy
BioPharma Dive
Novartis
SMA
gene therapy
Zolgensma
clinical trials
FDA
Flag link:
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
drug pricing
regulatory
Celgene
Bristol-Myers Squibb
Teva Pharmaceutical
Amgen
Novartis
Mallinckrodt
AbbVie
US Congress
Flag link:
OptumRx's 3 recently approved drugs to watch
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
Flag link:
Sandoz working to overcome barriers to greater biosimilars uptake in US
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Sandoz
biosimilars
Novartis
Flag link:
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
Fierce Pharma
ESMO
Novartis
breast cancer
Piqray
Faslodex
AstraZeneca
Flag link:
BioNTech acquires German manufacturing site to boost COVID-19 vaccine production
BioNTech acquires German manufacturing site to boost COVID-19 vaccine production
Biopharma Reporter
BioNTech
Novartis
Germany
vaccines
MRNA
COVID-19
Flag link:
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Pharma Live
Novartis
Beovu
Eylea
Regeneron
diabetic macular edema
clinical trials
Flag link:
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
Endpoints
Boehringer Ingelheim
digital therapeutics
Click Therapeutics
mobile apps
Novartis
Flag link:
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Fierce Pharma
Novartis
Roche
France
Lucentis
anti-competitive scheme
Flag link:
Big pharma spinouts grow up
Big pharma spinouts grow up
EP Vantage
Big Pharma
spinoffs
Merck KGaA
Pfizer
GSK
Novartis
Roche
Sanofi
JNJ
AstraZeneca
Flag link:
In the footsteps of AstraZeneca, Novartis commits to carbon-neutral supply chain by 2030
In the footsteps of AstraZeneca, Novartis commits to carbon-neutral supply chain by 2030
Endpoints
AstraZeneca
Novartis
carbon neutrality
environmental concerns
Flag link:
Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris
Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris
Fierce Biotech
Novartis
clinical trials
PNH
Alexion Soliris
LNP023
Flag link:
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
Fierce Pharma
Novartis
Entresto
ESC
heart failure
Flag link:
Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast
Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast
Fierce Pharma
Novartis
podcasts
psoriasis
celebrity endorsements
Cosentyx
Flag link:
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study
Pharmaceutical Business Review
Novartis
asciminib
ABL001
clinical trials
chronic myeloid leukemia
Flag link:
Blow for Novartis as PD-1 drug spartalizumab flunks trial
Blow for Novartis as PD-1 drug spartalizumab flunks trial
Pharmaforum
Novartis
clinical trials
spartalizumab
skin cancer
Flag link:
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Biopharma Dive
Novartis
FDA
Kesimpta
ofatumumab
MS
multiple sclerosis
Flag link:
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Regeneron
inclisiran
RNAi
Novartis
New England Journal of Medicine
Flag link:

Pages